Relapsed Or Refractory Aml With Idh2 Mutation Therapeutics
1. Idhifa patent expiration
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
IDHIFA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512107 | BRISTOL MYERS SQUIBB | Therapeutically active compositions and their methods of use |
Jan, 2033
(7 years from now) | |
| US10093654 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Aug, 2034
(8 years from now) | |
| US9732062 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Sep, 2034
(8 years from now) | |
| US9738625 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Aug, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10294215 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Jan, 2033
(7 years from now) | |
| US10610125 | BRISTOL MYERS SQUIBB | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2022 |
| Orphan Drug Exclusivity(ODE) | Aug 01, 2024 |
| Orphan Drug Exclusivity(ODE-151) | Aug 01, 2024 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: 01 August, 2021
Market Authorisation Date: 01 August, 2017
Dosage: TABLET
More Information on Dosage
IDHIFA family patents
